Active Ingredient: Orlistat
Another limitation is the open-label treatment; however, given that this was the first study of this kind, the data provided by the study are sufficient to justify the reassessment of longer treatment with higher doses, especially in the metformin group.
Also a further double-blinded study should be designed. In conclusion, treatment with orlistat resulted in a greater weight loss and improvement in body composition.
Treatment with metformin caused a greater decrease of android fat.
Insulin-resistant obese women demonstrated greater effects of treatment, irrespective of the drug used. English language assistance was provided by Proper Medical Writing Sp. References 1. An analysis of epidemiological and prognostic research.
Arch Med Sci. Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns.
Abdominal adiposity assessed by dual energy X-ray absorptiometry provides a sex-independent predictor of insulin sensitivity in older adults.
The official positions of the International Society for Clinical Densitometry: body composition analysis reporting.
J Clin Densitom. The official positions of the International Society for Clinical Densitometry: acquisition of dual-energy X-ray absorptiometry body composition and considerations regarding analysis and repeatability of measures.
Increased consumption of dairy foods and protein during diet- and exercise-induced weight loss promotes fat mass loss and lean mass gain in overweight and obese premenopausal women.